ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor

British Journal of Haematology

Volumn 143, Issue 4, 2008, Pages 552-558

  Pruss, Cynthia M ^a   Notley, Colleen R P ^a   Hegadorn, Carol A ^a   O'Brien, Lee A ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

ADAMTS13; Cleavage; Polymorphism; Von Willebrand disease; Von Willebrand factor

Indexed keywords

GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR 115; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM PROTEINS; DNA CLEAVAGE; HUMANS; MUTAGENESIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 54949110247     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07266.x     Document Type: Article

References (19)

1. Baronciani, L., Federici, A.B., Cozzi, G., Canciani, M.T. Mannucci, P.M. (2006) von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. Journal of Thrombosis and Haemostasis, 4, 2088 2090.
2. Cruz, M.A., Diacovo, T.G., Emsley, J., Liddington, R. Handin, R.I. (2000) Mapping the glycoprotein ib-binding site in the von Willebrand factor A1 domain. The Journal of Biological Chemistry, 275, 19098 19105.
3. Davies, J.A. Bowen, D.J. (2007) The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13. Haematologica, 92, 240 243.
4. Desch, K.C. Ginsburg, D 2007) Mutations that render von Willebrand factor (VWF) resistant to ADAMTS13 cleavage. Journal of Thrombosis and Haemostasis, 5, S2:O-M-069.
5. Furlan, M. (1996) von Willebrand factor: molecular size and functional activity. Annals of Hematology, 72, 341 348.
6. Furlan, M., Robles, R. Lamie, B. (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 4223 4234.
7. Hassenpflug, W.A., Budde, U., Obser, T., Angerhaus, D., Drewke, E., Schneppenheim, S. Schneppenheim, R. (2006) Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood, 107, 2339 2345.
8. Kato, S., Matsumoto, M., Matsuyama, T., Isonishi, A., Hiura, H. Fujimura, Y. (2006) Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion, 46, 1444 1452.
9. Kokame, K., Matsumoto, M., Fujimura, Y. Miyata, T. (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood, 103, 607 612.
10. Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A. Miyata, T. (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. British Journal of Haematology, 129, 93 100.
11. O'Brien, L.A., James, P.D., Othman, M., Berber, E., Cameron, C., Notley, C.R., Hegadorn, C.A., Sutherland, J.J., Hough, C., Rivard, G.E., O'Shaunessey, D. Lillicrap, D. & Association of Hemophilia Clinic Directors of Canada 2003) Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood, 102, 549 557.
12. Obert, B., Tout, H., Veyradier, A., Fressinaud, E., Meyer, D. Girma, J.P. (1999) Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thrombosis and Haemostasis, 82, 1382 1385.
13. Plaimauer, B., Zimmermann, K., Volkel, D., Antoine, G., Kerschbaumer, R., Jenab, P., Furlan, M., Gerritsen, H., Lammle, B., Schwarz, H.P. Scheiflinger, F. (2002) Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood, 100, 3626 3632.
14. Rayes, J., Hommais, A., Legendre, P., Tout, H., Veyradier, A., Obert, B., Ribba, A.S. Girma, J.P. (2007) Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. Journal of Thrombosis and Haemostasis, 5, 321 328.
15. Stakiw, J., Bowman, M., Hegadorn, C., Pruss, C., Notley, C., Groot, E., Lenting, P.J., Rapson, D., Lillicrap, D. James, P. (2007) The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. Journal of Thrombosis and Haemostasis, 6, 90 96.
16. Sutherland, J.J., O'Brien, L.A., Lillicrap, D. Weaver, D.F. (2004) Molecular modeling of the von Willebrand factor A2 domain and the effects of associated type 2A von Willebrand disease mutations. Journal of Molecular Modeling, 10, 259 270.
17. Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 4235 4244.
18. Wu, J.J., Fujikawa, K., McMullen, B.A. Chung, D.W. (2006) Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proceedings of the National Academy of Sciences of the United States of America, 103, 18470 18474.
19. Zanardelli, S., Crawley, J.T., Chion, C.K., Lam, J.K., Preston, R.J. Lane, D.A. (2006) ADAMTS13 substrate recognition of von Willebrand factor A2 domain. Journal of Biological Chemistry, 281, 1555 1563.